First record of baobab (Adansonia digitata L.) in Uganda

J. Gebauer,C. Whitney,J. Tabuti

DOI: https://doi.org/10.1007/s10722-016-0387-y

2016-03-17

Genetic Resources and Crop Evolution

Abstract:

What problem does this paper attempt to address?

Thrombophilic State in Breast Cancer

Manfred Schmitt,Walther Kuhn,Nadia Harbeck,Henner Graeff

DOI: https://doi.org/10.1055/s-2007-994917

1999-04-01

Seminars in Thrombosis and Hemostasis

Abstract:Tumor cell metastasis and thrombosis are the major causes of death in cancer patients. Thrombosis in cancer patients may occur when physiologic antithrombotic systems are defective or when prothrombotic activities defeat normal physiologic antithrombotic mechanisms. Malignancies by themselves may already predispose to a hypercoagulable state in cancer patients. Tumor cells can either directly activate the blood clotting system or indirectly stimulate mononuclear cells to synthesize and express various procoagulants, subsequently leading to prothrombin activation, fibrin formation, and generation of a thrombus. In addition, other comorbid predisposing factors effecting thrombosis in cancer patients have to be considered, including surgery, bed rest, infection, long-term indwelling central venous catheters, anticoagulation, and chemotoxic or steroidal anticancer drugs used in adjuvant or palliative cancer treatment. Reliable information on the incidence of thromboembolism in cancer patients is available for breast cancer; less data have been reported for other malignancies. Chemo- and/or hormone therapy in patients with primary or metastatic breast cancer is associated with an increased thromboembolic risk, although the benefits of treatment far outweigh the risks. The current literature discussing the effect of chemo/hormone therapy on blood clotting factors and the associated risk of thrombosis is reviewed, with emphasis on new developments in the area of tissue-specific SERMs (selective estrogen receptor modulators). SERMs are employed as adjuvant therapy in primary breast cancer and in the palliation of advanced breast cancer and may be clinically useful as potential substitutes for long-term hormone replacement therapy, in the treatment of osteoporosis, and for cancer prevention therapy.

peripheral vascular disease,hematology
[Tissue factors and venous thromboembolism in cancer patients].

Huiqi Zhu,Kejing Ying

DOI: https://doi.org/10.3785/j.issn.1008-9292.2020.12.13

2020-01-01

Abstract:Malignant tumor is one of the important acquired risk factors of venous thromboembolism (VTE). As the transmembrane receptor of coagulation factor Ⅶ and activated coagulation factor Ⅶa , tissue factor is the main initiator of exogenous coagulation. Tissue factor positive particles expressed and released by tumor cells enter the circulation and mediate thrombosis in patients with surgical treatment and distant tumor metastasis; the enhanced procoagulant activity of tissue factor after chemotherapy makes many cancer patients more likely to develop thromboembolic disease. Tissue factors can also be used to predict the risk of VTE in patients with pancreatic cancer, colorectal cancer and ovarian cancer.This article summarizes the role of tissue factor in VTE of cancer patients at different treatment stages, and further clarifies the relationship between tissue factor and the risk of VTE in cancer patients.
Potential Mechanisms of Cancer-Related Hypercoagulability

Nicola J. Nasser,Jana Fox,Abed Agbarya

DOI: https://doi.org/10.3390/cancers12030566

2020-02-29

Cancers

Abstract:The association between cancer and thrombosis has been known for over a century and a half. However, the mechanisms that underlie this correlation are not fully characterized. Hypercoagulability in cancer patients can be classified into two main categories: Type I and Type II. Type I occurs when the balance of endogenous heparin production and degradation is disturbed, with increased degradation of endogenous heparin by tumor-secreted heparanase. Type II hypercoagulability includes all the other etiologies, with factors related to the patient, the tumor, and/or the treatment. Patients with poor performance status are at higher risk of venous thromboembolism (VTE). Tumors can result in VTE through direct pressure on blood vessels, resulting in stasis. Several medications for cancer are correlated with a high risk of thrombosis. These include hormonal therapy (e.g., tamoxifen), chemotherapy (e.g., cisplatin, thalidomide and asparaginase), molecular targeted therapy (e.g., lenvatinib, osimertinib), and anti-angiogenesis monoclonal antibodies (e.g., bevacizumab and ramucirumab).

oncology
[Prophylaxis of thrombosis induced by chemotherapy or central venous catheters]

Eric Voog,Eric Lazard,Laurence Juhel

DOI: https://doi.org/10.1016/j.lpm.2006.08.001

Abstract:Introduction: Deep venous thrombosis and pulmonary embolism are well-recognized complications of cancer, especially in patients with a venous access device or receiving chemotherapy. The pathogenic mechanisms of thrombosis in cancer patients involve a complex interaction between the patient's tumor cells and hemostatic system. Chemotherapy and central venous catheters increase the risk of thromboembolism. Prophylactic treatment for these patients remains controversial. Methods: We conducted a systematic literature review using the Medline database and abstract books for meetings of the American Society of Clinical Oncology and the American Society of Hematology since 2000. Our search focused on clinical trials of primary prevention of venous catheter-related thrombosis or prevention of chemotherapy-related venous thromboembolism in cancer patients. Results: Ten studies evaluating primary prevention of patients with central catheters were identified, and their results are contradictory. Currently only one study has examined prevention of chemotherapy-related venous thromboembolism, in women with metastatic breast cancer. Its results cannot be extrapolated to other tumors. Conclusion: Systematic prophylaxis cannot yet be recommended. In the near future we must improve our knowledge of the risk factors of these complications. Prophylaxis should be individualized for each patient. New anticoagulant drugs should be tested in cancer patients.
Cancer Therapy–Associated Thrombosis

Steven P. Grover,Yohei M. Hisada,Raj S. Kasthuri,Brandi N. Reeves,Nigel Mackman

DOI: https://doi.org/10.1161/ATVBAHA.120.314378

2021-02-12

Abstract:Patients with cancer have an increased risk of both arterial and venous thrombotic events compared with the general population. Both the site and stage of cancer are known to contribute to the increased risk of thrombotic events. In addition, several treatment-related factors enhance the risk of thrombosis, including hospitalization, surgery, central venous catheters, radiation, and anticancer agents. Chemotherapy serves as a mainstay treatment for a broad range of malignancies. Chemotherapeutic agents typically exert antineoplastic effects through either direct cytotoxicity or inhibition of cellular processes necessary for the proliferation of malignant cells. Unfortunately, in addition to targeting malignant cells, chemotherapeutic agents are also cytotoxic to nonmalignant cells. More recently, targeted agents have been developed that offer improved selectivity towards malignant cells. However, some of these agents are also associated with an increased risk of both arterial and venous thrombosis. Here, we review the association between specific anticancer agents and thrombotic events in patients with cancer. Despite an established association in most cases, the mechanism by which these agents increase thrombosis is incompletely understood. Anticancer agents may damage the endothelium, decrease anticoagulants or increase procoagulants leading to activation of coagulation, or activate platelets. An improved understanding of the mechanisms that drive the increased risk of thrombotic events associated with anticancer agents will enable treatment strategies that mitigate this risk.
Cancer, thrombosis, and anticoagulants

D L Ornstein,L R Zacharski

DOI: https://doi.org/10.1097/00063198-200007000-00009

Abstract:Rapid progress has been made recently in our understanding of the pathogenesis of coagulation activation in malignancy and mechanisms by which the coagulation mechanism may control malignant growth. Idiopathic thromboembolic disease may be the sentinel presentation in patients subsequently diagnosed with malignancy. Thrombosis complicating the course of malignancy may be notoriously difficult to treat, but the introduction of the low-molecular-weight heparins has greatly improved management and may obviate the need for invasive approaches, such as the use of inferior vena cava filters, in many cases. Tantalizing clues from clinical trials of anticoagulant therapy in cancer have suggested that components of coagulation pathways may support tumor growth. Many of these can be intercepted using drugs that are well known and non-toxic. The importance of performing high-quality controlled clinical trials that build on past studies and on data from basic research cannot be overemphasized.
Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment

Norbaini Binti Abdol Razak,Gabrielle Jones,Mayank Bhandari,Michael C. Berndt,Pat Metharom,Norbaini Abdol Razak,Michael Berndt

DOI: https://doi.org/10.3390/cancers10100380

2018-10-11

Cancers

Abstract:Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type being venous thromboembolism (VTE). Several risk factors for developing VTE also coexist with cancer patients, such as chemotherapy and immobilisation, contributing to the increased risk cancer patients have of developing VTE compared with non-cancer patients. Cancer cells are capable of activating the coagulation cascade and other prothrombotic properties of host cells, and many anticancer treatments themselves are being described as additional mechanisms for promoting VTE. This review will give an overview of the main thrombotic complications in cancer patients and outline the risk factors for cancer patients developing cancer-associated thrombosis, focusing on VTE as it is the most common complication observed in cancer patients. The multiple mechanisms involved in cancer-associated thrombosis, including the role of anticancer drugs, and a brief outline of the current treatment for cancer-associated thrombosis will also be discussed.

oncology
A High Content Drug Screen Identifies Ursolic Acid as an Inhibitor of Amyloid β Protein Interactions with Its Receptor CD36*

K. Wilkinson,Justin D. Boyd,M. Glicksman,K. Moore,J. E. El Khoury

DOI: https://doi.org/10.1074/jbc.M111.232116

IF: 5.485

2011-08-11

Journal of Biological Chemistry

Abstract:Background: Amyloid β binds CD36 and activates microglia to produce cytokines and neurotoxins leading to neurodegeneration. Results: We developed an assay to find inhibitors of amyloid β binding to CD36 and identified ursolic acid as such an inhibitor. Conclusions: Ursolic acid blocks CD36-mediated microglial activation by amyloid β. Significance: Ursolic acid is a potential therapeutic agent for Alzheimer disease. A pathological hallmark of Alzheimer disease (AD) is deposition of amyloid β (Aβ) in the brain. Aβ binds to microglia via a receptor complex that includes CD36 leading to production of proinflammatory cytokines and neurotoxic reactive oxygen species and subsequent neurodegeneration. Interruption of Aβ binding to CD36 is a potential therapeutic strategy for AD. To identify pharmacologic inhibitors of Aβ binding to CD36, we developed a 384-well plate assay for binding of fluorescently labeled Aβ to Chinese hamster ovary cells stably expressing human CD36 (CHO-CD36) and screened an Food and Drug Administration-approved compound library. The assay was optimized based on the cells' tolerance to dimethyl sulfoxide, Aβ concentration, time required for Aβ binding, reproducibility, and signal-to-background ratio. Using this assay, we identified four compounds as potential inhibitors of Aβ binding to CD36. These compounds were ursolic acid, ellipticine, zoxazolamine, and homomoschatoline. Of these compounds, only ursolic acid, a naturally occurring pentacyclic triterpenoid, successfully inhibited binding of Aβ to CHO-CD36 cells in a dose-dependent manner. The ursolic acid effect reached a plateau at ∼20 μm, with a maximal inhibition of 64%. Ursolic acid also blocked binding of Aβ to microglial cells and subsequent ROS production. Our data indicate that cell-based high-content screening of small molecule libraries for their ability to block binding of Aβ to its receptors is a useful tool to identify novel inhibitors of receptors involved in AD pathogenesis. Our data also suggest that ursolic acid is a potential therapeutic agent for AD via its ability to block Aβ-CD36 interactions.
Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment

Dragica Pavlovic,Danijela Niciforovic,Marina Markovic,Dragana Papic

DOI: https://doi.org/10.1177/11795549231220297

2023-01-01

Abstract:Cancer patients represent a growing population with drastically difficult care and a lowered quality of life, especially due to the heightened risk of vast complications. Thus, it is well established so far that one of the most prominent complications in individuals with cancer is venous thromboembolism. Since there are various improved methods for screening and diagnosing cancer and its complications, the incidence of cancer-associated thrombosis has been on the rise in recent years. Therefore, the high mortality and morbidity rates among these patients are not a surprise. Consequently, there is an excruciating need for understanding the mechanisms behind this complex process, as well as the imperative for adequate analysis and application of the most suitable steps for cancer-associated thrombosis prevention. There are various and numerous mechanisms offering potential answers to cancer-associated thrombosis, some of which have already been elucidated in various preclinical and clinical scenarios, yet further and more elaborate studies are crucial to understanding and preventing this complex and harsh clinical entity. This article elaborates on the growing incidence, mortality, morbidity, and risk factors of cancer-associated thrombosis while emphasizing the pathophysiological mechanisms in the light of various types of cancer in patients and summarizes the most novel therapy and prevention guidelines recommendations.

oncology
Operationalizing the Section 5 Retrogression Standard of the Voting Rights Act in the Light of Georgia v. Ashcroft: Social Science Perspectives on Minority Influence, Opportunity and Control

B. Grofman

DOI: https://doi.org/10.1089/ELJ.2006.5.250

2006-07-25

Abstract:IN GEORGIA V. ASHCROFT, 539 U. S. 461 (2003), by a 5-4 vote, the Supreme Court laid down a new interpretation of the meaning of the retrogression standard in Section 5 of the Voting Rights Act. Justice O’Connor’s majority opinion replaces the exclusive focus in earlier Section 5 jurisprudence on reduction in the realistic opportunity of minority voters1 to elect candidates of choice2 with what is commonly described as a dualistic approach that allows jurisdictions to determine which of two variants of retrogression they wish to claim their plan avoids: (1) retrogression in ability of minorities to elect candidates of choice, or (2) retrogression in the magnitude of overall minority influence.3 Although the years prior to Georgia v. Ashcroft had already seen both important changes in how the Section 5 standard was legally defined and in how the U.S. Department
Overview of Dugs Increasing the Risk of VTE or Thrombosis in Patients with Cancer

Xiang-li CUI,Zi-rui WAN,Ke-lu HOU,Hui YANG,Xiao-jia YU,Yun-ying ZHENG,Li LIU,Yuan-hua YANG

2017-01-01

Abstract:Venous thromboembolism (VTE) is a frequent and potential life threatening complication associated with tumor malignancies. In patients with cancer, VTE portends a poor prognosis, in fact, only 12% of those who suffer an event will survive beyond one year. There are several different risk factors for the development of VTE in cancer patients that are well-described in the literature. Cancer is often associated with hypercoagulability due to changes in coagulation factors, local venous stasis, surgery, and the presence of a central venous catheter. In addition, chemotherapy drugs may further increase the risk of thromboembolic disease. The annual incidence of VTE in patients receiving chemotherapy is estimated at 11%. This risk can climb to 20% or higher depending on the type of drugs being administered. In addition to chemotherapy, there are many other anti-neoplastic and supportive therapies that are also associated with an increased risk for the development of VTE. At present, several original basic science studies and clinical trials are underway in an effort to enhance our understanding of the mechanisms by which different chemotherapeutic agents can generate a prothrombotic state. The purpose of this article is to review the pertinent literature related to VTE in malignancy, chemotherapy and other cancer-related treatments associated with VTE, and to provide reference for prevention of thrombosis risk in medication therapy of tumors.
Cancer progression and tumor hypercoagulability: a platelet perspective

Yifan Zhang,Jingtong Zeng,Shihao Bao,Bo Zhang,Xianjie Li,Hanqing Wang,Yuan Cheng,Hao Zhang,Lingling Zu,Xiaohong Xu,Song Xu,Zuoqing Song

DOI: https://doi.org/10.1007/s11239-024-02993-0

2024-05-19

Journal of Thrombosis and Thrombolysis

Abstract:Venous thromboembolism, which is common in cancer patients and accompanies or even precedes malignant tumors, is known as cancer-related thrombosis and is an important cause of cancer- associated death. At present, the exact etiology of the elevated incidence of venous thrombosis in cancer patients remains elusive. Platelets play a crucial role in blood coagulation, which is intimately linked to the development of arterial thrombosis. Additionally, platelets contribute to tumor progression and facilitate immune evasion by tumors. Tumor cells can interact with the coagulation system through various mechanisms, such as producing hemostatic proteins, activating platelets, and directly adhering to normal cells. The relationship between platelets and malignant tumors is also significant. In this review article, we will explore these connections.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
Mechanisms and management of thrombosis in cancer: focus on gastrointestinal malignancies

Simone Monegatti,Nicola Martinelli,Simonetta Friso,Henri Mh Spronk,Hugo Ten Cate

DOI: https://doi.org/10.1124/jpet.124.002203

2024-07-19

Abstract:Cancer patients have an increased risk of venous thromboembolism (VTE) which is their second cause of death after disease progression itself. Several thrombotic risk factors coexist in cancer patients, including the ability of both cancer and tumoral microenvironment's cells to directly or indirectly activate platelets and the enzymes of the coagulation cascade, resulting in a hyper-coagulable state of blood. This narrative review gives an overview of the main mechanisms leading to VTE in cancer patients, including the role that platelets and the clotting proteins may have in tumor growth and metastasis. Noteworthy, the haemostatic balance is altered in cancer patients who may, next to a thrombosis tendency, also have an increased risk of bleeding. To highlight the complexity and the precariousness of the haemostatic balance of these patients, we discuss two specific gastrointestinal malignancies: hepatocellular carcinoma, which is frequently associated with liver cirrhosis, a condition that causes profound alterations of haemostasis, and colorectal cancer, which is characterized by a fragile mucosa that is prone to bleeding. Understanding the molecular mechanisms of cancer-associated thrombosis may give a unique opportunity to develop new innovative drugs, acting differently on distinct pathways and potentially allowing to reduce the risk of bleeding related to antithrombotic therapies. Significance Statement The topic is significant because understanding the molecular mechanisms leading to cancer associated thrombosis and bleeding, focusing on gastrointestinal malignancies, enables the development of more rationale and innovative antithrombotic strategies for cancer associated thrombosis. Eventually, this will support an improved and patient-tailored antithrombotic management in vulnerable oncologic patients.
Advances in Cancer Related Venous Thromboembolism Research

Hai-hui ZHOU,Wei-hong GE

DOI: https://doi.org/10.13664/j.cnki.pcr.2016.01.011

2016-01-01

Abstract:Malignant tumor is one of the high risk factors for venous thromboembolism (VTE). The incidence of VTE has been rising as the number of cancer patients increased. Because the pathophysiology of thrombosis is multifactorial, there is no ‘one fits all’ prophylaxis or treatment. Most clinical guidelines agree that low molecular weight heparins (LMWHs) are the preferred anticoagulants for the prevention and treatment of VTE in cancer patients during hospitalization. However, thromboprophylaxis is not customarily advised for ambulatory cancer patients. New oral anticoagulants are currently not recommended for cancer patients until their safety and effectiveness are fully verified. In this comprehensive review, we provide an overview of epidemiology, risk assessment, prevention and treatment of cancer-related VTE and research progress in new type anticoagulants.
Adherence to early mobilisation: Key for successful enhanced recovery after liver resection.

V. Yip,D. Dunne,S. Samuels,C. Y. Tan,C. Lacasia,Joseph Tang,C. Burston,H. Malik,G. Poston,S. Fenwick

DOI: https://doi.org/10.1016/j.ejso.2016.07.015

IF: 4.037

2016-10-01

European Journal of Surgical Oncology

Abstract:
Cancer-Associated Thrombosis: Management of a Patient With an Isolated Calf Deep Vein Thrombosis

Gerald A. Soff

DOI: https://doi.org/10.1200/jco.23.01905

IF: 45.3

2024-01-07

Journal of Clinical Oncology

Abstract:The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice. Venous thromboembolism occurs frequently in patients with cancer and is the second leading cause of death, after the cancer itself. There is a well-established consensus of the need for anticoagulation in patients with a proximal deep vein thrombosis or pulmonary embolism. But with improved imaging technology and widescale use of contrast imaging for cancer staging, many incidental pulmonary emboli are detected in patients with cancer. Furthermore, many isolated distal deep vein thromboses and subsegmental pulmonary emboli are identified. There have been questions if these small or asymptomatic thromboses require anticoagulation management similar to more proximal or symptomatic thromboses. In this Oncology Grand Rounds, we will review the existing evidence for these situations. We will also review management strategies for cancer-associated thrombosis, reflecting the evolving drugs and evidence over the past 20 years.

oncology
Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating Disease-Free and Overall Survival

Katarzyna Wrzeszcz,Piotr Rhone,Katarzyna Kwiatkowska,Barbara Ruszkowska-Ciastek

DOI: https://doi.org/10.3390/life13051106

2023-04-29

Life

Abstract:(1) Background: Cancer treatment, including chemotherapy, endocrine therapy, targeted therapy and radiotherapy, has been identified as an important independent risk factor for venous thromboembolism in cancer patients. The aim of the study was to evaluate the effect of adjuvant therapy on the coagulation and fibrinolysis components in invasive breast cancer. (2) Methods: Tissue factor pathway inhibitor (TFPI), tissue factor (TF), tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1) antigen (concentration) and TFPI and TF activities were examined in the blood samples of 60 breast cancer patients treated by adjuvant chemotherapy, endocrine therapy, radiotherapy and immunotherapy. Blood samples were taken 24 h before primary surgery and 8 months after tumour removal surgery. (3) Results: Adjuvant therapy administrated to breast cancer patients significantly increased the concentration of plasma TF, the PAI-1 antigen and also the activity of TFPI and TF, but significantly decreased the level of the t-PA antigen. Combined chemotherapy and endocrine therapy, but not monotherapy, has an important effect on haemostatic biomarker levels. (4) Conclusions: Breast cancer patients receiving adjuvant therapy have an elevated risk of developing a hypercoagulability and hypofibrinolysis state leading to venous thromboembolism.

biology
Thromboprophylaxis in Cancer Patients Undergoing Surgery

Kay T Htun,Agnes Y Y Lee,Kay Htun,Agnes Lee

DOI: https://doi.org/10.1055/s-0037-1602666

2017-06-08

Seminars in Thrombosis and Hemostasis

Abstract:Abstract Venous thromboembolism (VTE) is a common, complex, and costly complication in cancer patients undergoing surgery. VTE risk varies with types of cancer surgery as well as patient-, cancer-, and treatment-associated factors. Current VTE preventive measures with pharmacological, mechanical, and combination of both are shown to be effective. Clinical questions remain and more research is needed, focusing on the role of thromboprophylaxis for minimally invasive surgery and major cancer surgery other than abdominal/pelvic surgery, as well as optimal duration of thromboprophylaxis in high-risk patients. Routine individual VTE risk assessment and better adherence to thromboprophylaxis guidelines may offer improved outcomes in cancer patients undergoing surgery. A summary of currently available evidence and consensus guidelines on the primary prevention of VTE in cancer patients undergoing various types of surgery is presented here.

peripheral vascular disease,hematology
BRAIN STEM ELECTRICAL ACTIVITY DURING DEEP SLEEP.

Brooks Dc,E. Bizzi

1963-10-05

ARCHIVES ITALIENNES DE BIOLOGIE

Abstract:
Anticoagulation and bleeding in the cancer patient

Andres Escobar,Ahmed M Salem,Kodwo Dickson,Tami N Johnson,Kathyrn J Burk,Lara Bashoura,Saadia A Faiz

DOI: https://doi.org/10.1007/s00520-022-07136-w

Abstract:Cancer patients have an increased risk of bleeding compared to non-cancer patients with anticoagulant therapy. A bleeding risk assessment before initiation of anticoagulation is recommended. Currently low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) are the mainstays of treatment for cancer-associated venous thromboembolism (VTE). Since DOACs are administered orally, they offer some convenience and ease of administration; however, LMWH may be preferred in certain cancers. Given the prevalence of anticoagulant therapies in cancer patients, clinical providers must be able to recognize potentially critical bleeding sites and modalities to reverse major hemorrhage. Reversal agents or antidotes to bleeding may be required when bleeding is persistent or life-threatening. These include vitamin K, fresh frozen plasma (FFP), protamine, prothrombin complex concentrate (PCC) or andexanet alfa, and idarucizumab. Inferior vena cava (IVC) filter insertion can be also considered in those with major bleeding. Evidence for timing and need for re-initiation of anticoagulant therapy after a major bleeding remains sparse, but a multi-disciplinary approach and shared decision-making can be implemented in the interim.

First record of baobab (Adansonia digitata L.) in Uganda

Thrombophilic State in Breast Cancer

[Tissue factors and venous thromboembolism in cancer patients].

Potential Mechanisms of Cancer-Related Hypercoagulability

[Prophylaxis of thrombosis induced by chemotherapy or central venous catheters]

Cancer Therapy–Associated Thrombosis

Cancer, thrombosis, and anticoagulants

Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment

A High Content Drug Screen Identifies Ursolic Acid as an Inhibitor of Amyloid β Protein Interactions with Its Receptor CD36*

Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment

Operationalizing the Section 5 Retrogression Standard of the Voting Rights Act in the Light of Georgia v. Ashcroft: Social Science Perspectives on Minority Influence, Opportunity and Control

Overview of Dugs Increasing the Risk of VTE or Thrombosis in Patients with Cancer

Cancer progression and tumor hypercoagulability: a platelet perspective

Mechanisms and management of thrombosis in cancer: focus on gastrointestinal malignancies

Advances in Cancer Related Venous Thromboembolism Research

Adherence to early mobilisation: Key for successful enhanced recovery after liver resection.

Cancer-Associated Thrombosis: Management of a Patient With an Isolated Calf Deep Vein Thrombosis

Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating Disease-Free and Overall Survival

Thromboprophylaxis in Cancer Patients Undergoing Surgery

BRAIN STEM ELECTRICAL ACTIVITY DURING DEEP SLEEP.

Anticoagulation and bleeding in the cancer patient